Search
for
Sort by
Research 211–240 of 1000+
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
- Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARα and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways
- Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways
- Detection of Serum Levels of Interleukins-17, 21, 6 and Tumor Necrosis Factor-α in Patients with Patchy Alopecia Areata and Their Association with Disease Severity
- Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
- Alopecia Areata: JAK Inhibitors—PRP and Exosomes
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Janus Kinase inhibitors in dermatology: a review
- Alopecia Areata and Alopecia Areata Incognita
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
- Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review
- Alopecia Universalis with Frequently Relapsing Nephrotic Syndrome of Infantile Onset: A Rare Presentation
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Alopecia Areata
- Exploring novel management options for alopecia areata
- Tofacitinib for the treatment of lichen planopilaris: A case series
- Topical tofacitinib for the treatment of alopecia areata affecting facial hair
- Novel Quinazoline Derivative Induces Differentiation of Keratinocytes and Enhances Skin Barrier Functions against Th2 Cytokine-Mediated Signaling
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study